Airain ltd decreased its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 27.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,752 shares of the medical research company’s stock after selling 21,884 shares during the period. Airain ltd’s holdings in Thermo Fisher Scientific were worth $10,250,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. BB&T Securities LLC raised its holdings in shares of Thermo Fisher Scientific by 4.4% during the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock valued at $13,798,000 after purchasing an additional 3,819 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in Thermo Fisher Scientific by 0.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after purchasing an additional 5,213 shares during the period. Mitchell Capital Management Co. lifted its position in Thermo Fisher Scientific by 40.3% during the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after purchasing an additional 12,910 shares during the period. Toronto Dominion Bank lifted its position in Thermo Fisher Scientific by 53.5% during the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock valued at $16,450,000 after purchasing an additional 37,307 shares during the period. Finally, IBM Retirement Fund lifted its position in Thermo Fisher Scientific by 117.7% during the second quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock valued at $1,860,000 after purchasing an additional 5,157 shares during the period. 83.36% of the stock is owned by institutional investors and hedge funds.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares of the company’s stock, valued at $11,796,156.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the sale, the vice president now directly owns 25,518 shares in the company, valued at $4,537,100.40. The disclosure for this sale can be found here. Insiders have sold a total of 52,738 shares of company stock valued at $9,302,112 in the last quarter. Company insiders own 0.49% of the company’s stock.

Several equities research analysts recently issued reports on TMO shares. Jefferies Group LLC restated a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Goldman Sachs Group, Inc. (The) began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. Barclays PLC reiterated an “overweight” rating and set a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price target on the stock in a report on Thursday, September 21st. Finally, Cowen and Company reissued an “outperform” rating and set a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $202.21.

Thermo Fisher Scientific Inc (TMO) opened at 190.33 on Wednesday. The stock has a 50 day moving average price of $185.02 and a 200 day moving average price of $173.34. The company has a market cap of $74.25 billion, a P/E ratio of 33.16 and a beta of 1.05. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same period in the prior year, the company earned $2.03 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

TRADEMARK VIOLATION WARNING: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/thermo-fisher-scientific-inc-tmo-shares-sold-by-airain-ltd.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.